Click here for an analysis of Cartesian Therapeutics' recent stock rebound and RNA cell therapy assets, including mixed ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

At six months, the median PFS rates were 89.5% and 87.6% in the ... for the treatment of KRd56 and KRd27 in patients with relapsed or refractory multiple myeloma. However, it’s important to note that ...

Truist Securities analyst Asthika Goonewardene in an investor note said data for anito-cel—particularly its safety ...

November is National Epilepsy Awareness Month (NEAM), and the call to action is "Share Your Purple Power.” This year’s theme celebrates the unwavering strength, resilience, and courage of epilepsy ...

Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...

The Jefferson County Senior Services Division is hosting The MMRF Multiple Myeloma Community Connect event on Thursday, Nov.

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of ...